MLYS Mineralys Therapeutics Inc
108
$13.52
$0.75
(5.26%)
| Watchers | 108 |
| 52-Wk Low | $5.85 |
| 52-Wk High | $17.44 |
| Market Cap | $708.24M |
| Volume | 121,642.00 |
| 52-Wk High | $17.44 |
| 52-Wk Low | $5.85 |
Mineralys Therapeutics (NASDAQ:MLYS) Given "Outperform" Rating at Lifesci CapitalZolmax • about 1 month ago
Lifesci Capital restated their outperform rating on shares of Mineralys Therapeutics (NASDAQ:MLYS - Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Lifesci...
Share to Feed
Mineralys Therapeutics (NASDAQ:MLYS Get Free Report)s stock had its outperform rating restated by analysts at Lifesci Capital in a research report issued on Tuesday...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025...
Mineralys Therapeutics files for $500M mixed shelf offering...
MLYS Announces Financial Results for Q4 and Full Year 2023, with Key Clinical Milestones on TrackRelated Stocks: MLYS...
RADNOR, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
Investors eyeing a purchase of Mineralys Therapeutics Inc (MLYS) shares, but cautious about paying the going market price of 14.33/share, might benefit from considering selling puts among the...
Mineralys Therapeutics stock jumps on $120M private placement financing...
RADNOR, Pa., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...